Ipsen to acquire French biotech ImCheck

French drugmaker Ipsen (Euronext: IPN) today announced a definitive agreement to acquire all issued and outstanding shares of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies.

The anticipated acquisition is focused on the lead Phase I/II program ICT01 in first line acute myeloid leukemia (AML) patients who are ineligible for intensive chemotherapy. ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer, and received Orphan Drug designations from the US Food and Drug Administration and European Medicines Agency in July 2025.

Shares of Ipsen were up 5.3% at 119.10 euros by early afternoon, on the day when the company also released encouraging financial results.